Skip to main content
PMC home page
Theranostics logoLink to Theranostics
. 2021 Feb 9;11(8):3963. doi: 10.7150/thno.58558

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong 1,2,#, Hui-Min Lei 1,2,#, Qian Liang 1,2,#, Ya-Bin Tang 1,2, Ye Zhou 1,2, Yang Wang 1,2, Shengzhe Zhang 3, Wen-Bin Li 1, Yunguang Tong 4,5, Guanglei Zhuang 3, Liang Zhang 1,2, Hong-Zhuan Chen 1,2,✉, Liang Zhu 1,2,✉, Ying Shen 1,2,✉
PMCID: PMC7914359  PMID: 33664874

“HCC827ER9” was inadvertently mistyped as “HCC827ER4” in Figure 1D. The correction has now been made online. This corrigendum does not affect any results or conclusions of the paper. The authors sincerely apologize for any confusion and inconvenience may have caused.

Figure 1.

Figure 1

Open in a new tab

D. Corrected image

Articles from Theranostics are provided here courtesy of Ivyspring International Publisher

RESOURCES